About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The goal of the Shock, Organic Dysfunction and Resuscitation Research Group (SODIR) is comprehensive, innovative research into the areas of shock, acute respiratory failure, acute kidney failure, organic dysfunction, resuscitation and critical patient monitoring. In addition, the research group has a special interest in applying artificial intelligence as an instrument to find innovative solutions for critical patients.
PMID: 33512013 Journal: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION Year: 2021 Reference: Eur J Clin Invest. 2021 Jun;51(6):e13501. doi: 10.1111/eci.13501. Epub 2021 Feb 8. Impact factor: 4.686 Publication type: Paper in international publication Authors: Gomez, Jose Manuel, Doncel, Cristina, Trapiello, Wysali, Kelvin, Alyson A, Booth, Ryan, Ostadgavahi, Ali Toloue, Oneizat, Ruth, Puertas, Carolina, Barbe, Ferran, Ferrer, Ricard et al. DOI: 10.1111/eci.13501
PMID: 33057749 Journal: INTENSIVE CARE MEDICINE Year: 2021 Reference: Intensive Care Med. 2021 Jan;47(1):97-100. doi: 10.1007/s00134-020-06271-4. Epub 2020 Oct 15. Impact factor: 17.44 Publication type: Letter or abstract Authors: Torres, Antoni, Artigas, Antoni, Ferrer, Ricard et al. DOI: 10.1007/s00134-020-06271-4
The study will be conducted in the Intensive Care Medicine Service of the Vall d’Hebron University Hospital and will validate the prognostic value of the NLRP3 biomarker.
SOFA-2 is being updated after thirty years to incorporate advances in diagnosis, monitoring and life support.
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
